These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17239591)

  • 1. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
    Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereochemical determination of Archazolid A and B, highly potent vacuolar-type ATPase inhibitors from the Myxobacterium Archangium gephyra.
    Hassfeld J; Farès C; Steinmetz H; Carlomagno T; Menche D
    Org Lett; 2006 Oct; 8(21):4751-4. PubMed ID: 17020294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of a water-soluble derivative of the potent V-ATPase inhibitor archazolid.
    Persch E; Basile T; Bockelmann S; Huss M; Wieczorek H; Carlomagno T; Menche D
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7735-8. PubMed ID: 23122818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Archazolid A-15-O-β-D-glucopyranoside and iso-archazolid B: potent V-ATPase inhibitory polyketides from the myxobacteria Cystobacter violaceus and Archangium gephyra.
    Horstmann N; Essig S; Bockelmann S; Wieczorek H; Huss M; Sasse F; Menche D
    J Nat Prod; 2011 May; 74(5):1100-5. PubMed ID: 21513292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lobatamide C: total synthesis, stereochemical assignment, preparation of simplified analogues, and V-ATPase inhibition studies.
    Shen R; Lin CT; Bowman EJ; Bowman BJ; Porco JA
    J Am Chem Soc; 2003 Jul; 125(26):7889-901. PubMed ID: 12823009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and activity of the archazolid western hemisphere.
    Tran AB; Melly GC; Doucette R; Ashcraft B; Sebren LJ; Havko N; Young JC; O'Neil GW
    Org Biomol Chem; 2011 Oct; 9(22):7671-4. PubMed ID: 21931924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first hydroxylated archazolid from the myxobacterium Cystobacter violaceus: isolation, structural elucidation and V-ATPase inhibition.
    Menche D; Hassfeld J; Steinmetz H; Huss M; Wieczorek H; Sasse F
    J Antibiot (Tokyo); 2007 May; 60(5):328-31. PubMed ID: 17551213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs.
    Scheeff S; Rivière S; Ruiz J; Abdelrahman A; Schulz-Fincke AC; Köse M; Tiburcy F; Wieczorek H; Gütschow M; Müller CE; Menche D
    J Med Chem; 2020 Feb; 63(4):1684-1698. PubMed ID: 31990540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPR Studies of V-ATPase with Spin-Labeled Inhibitors DCC and Archazolid: Interaction Dynamics with Proton Translocating Subunit c.
    Gölz JP; Bockelmann S; Mayer K; Steinhoff HJ; Wieczorek H; Huss M; Klare JP; Menche D
    ChemMedChem; 2016 Feb; 11(4):420-8. PubMed ID: 26662886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Synthesis of Archazolid F.
    Scheeff S; Menche D
    Org Lett; 2019 Jan; 21(1):271-274. PubMed ID: 30548075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vacuolar-type ATPase inhibitor archazolid increases tumor cell adhesion to endothelial cells by accumulating extracellular collagen.
    Luong B; Schwenk R; Bräutigam J; Müller R; Menche D; Bischoff I; Fürst R
    PLoS One; 2018; 13(9):e0203053. PubMed ID: 30204757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of photoactivatable acyclic analogues of the lobatamides.
    Shen R; Inoue T; Forgac M; Porco JA
    J Org Chem; 2005 Apr; 70(9):3686-92. PubMed ID: 15845008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and V-ATPase inhibition of simplified lobatamide analogues.
    Shen R; Lin CT; Bowman EJ; Bowman BJ; Porco JA
    Org Lett; 2002 Sep; 4(18):3103-6. PubMed ID: 12201727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.
    Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E
    Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of bafilomycin A1 derivatives as inhibitors of vacuolar H+-ATPase.
    Gagliardi S; Gatti PA; Belfiore P; Zocchetti A; Clarke GD; Farina C
    J Med Chem; 1998 May; 41(11):1883-93. PubMed ID: 9599238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modular total synthesis of archazolid A and B.
    Menche D; Hassfeld J; Li J; Mayer K; Rudolph S
    J Org Chem; 2009 Oct; 74(19):7220-9. PubMed ID: 19739663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the inhibitory effect of highly potent and selective archazolides binding to the vacuolar ATPase.
    Dreisigacker S; Latek D; Bockelmann S; Huss M; Wieczorek H; Filipek S; Gohlke H; Menche D; Carlomagno T
    J Chem Inf Model; 2012 Aug; 52(8):2265-72. PubMed ID: 22747331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.
    Schneider LS; von Schwarzenberg K; Lehr T; Ulrich M; Kubisch-Dohmen R; Liebl J; Trauner D; Menche D; Vollmar AM
    Cancer Res; 2015 Jul; 75(14):2863-74. PubMed ID: 26018087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vacuolar ATPase as a drug discovery target.
    Niikura K
    Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.
    Zhang S; Schneider LS; Vick B; Grunert M; Jeremias I; Menche D; Müller R; Vollmar AM; Liebl J
    Oncotarget; 2015 Dec; 6(41):43508-28. PubMed ID: 26496038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.